Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

AbbVie : Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:57pm CEST

Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance)

By a News Reporter-Staff News Editor at Drug Week -- A new study on Thiazoles is now available. According to news reporting from North Chicago, Illinois, by NewsRx journalists, research stated, "Ritonavir (RTV) is a weakly basic drug with a pH-dependent solubility. In vitro dissolution and supersatuation behaviors of three Norvir oral products including the tablet, powder, and solution were investigated by two biorelevant dissolution methods with pH alteration: a two-stage dissolution test and a biphasic dissolution-partition test."

Financial support for this research came from AbbVie (see also Thiazoles).

The news correspondents obtained a quote from the research from Abbvie Inc., "The two-stage dissolution test revealed a high degree of supersaturation of RTV from these products accompanied by the occurrence of liquid-liquid phase separation (LLPS) in biorelevant dissolution media. Higher, stable apparent RTV concentrations were observed in the FeSSIF-V2 as compared to those in the FaSSIF-V2, which suggested a food effect with higher exposure in the fed state. This is inconsistent with the evaluation in vivo. The biphasic test revealed significantly lower degrees of supersaturation of RTV in the aqueous media from these dosage forms as compared to results of the two-stage dissolution test. RTV concentrations in octanol at 6 h obtained from the tablet and powder with the use of the biorelevant media are consistent with corresponding in vivo AUC and Cmax under the fasting and moderate fat fed (MFF) states and predict the food effect. The underlying mechanisms responsible for the food effect are also proposed. Fractional partition profiles of RTV obtained in octanol from these three Norvir oral products are in agreement with the corresponding fractional absorption profiles in vivo under both the fasting and MFF states."

According to the news reporters, the research concluded: "This study reveals a complex interplay among the dissolution, precipitation, and partition processes from these formulations that dictate the oral exposure of RTV."

For more information on this research see: In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Molecular Pharmaceutics, 2017;():. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

Our news journalists report that additional information may be obtained by contacting H. Xu, NCE-Formulation Sciences, Drug Product Development and Clinical Pharmacology and Pharmacometrics, Abbvie Inc , 1 North Waukegan Road, North Chicago, Illinois 60064, United States. Additional authors for this research include S. Vela, Y. Shi, P. Marroum and P. Gao.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.molpharmaceut.7b00552. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Antiinfectives, Antiretrovirals, Antivirals, Illinois, Ritonavir, Thiazoles, North Chicago, United States, Drugs and Therapies, Protease Inhibitors, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
06/22EISAI : AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injectio..
AQ
06/22ABBVIE : 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-An..
AQ
06/22EISAI : AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injectio..
AQ
06/21ABBVIE : Announces U.S. FDA Approval of VENCLEXTA® venetoclax tablets in Combina..
AQ
06/21ABBVIE : Researchers at AbbVie Target Blood Cancer (Statins enhance efficacy of ..
AQ
06/21ABBVIE : Findings from AbbVie Provide New Insights into Drug Conjugates (Mechani..
AQ
06/21ABBVIE : Announces New Undetectable Minimal Residual Disease Data from Phase 3 R..
AQ
06/21Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug..
AC
06/20BRISTOL MYERS SQUIBB : Myers, AbbVie eye new use for myeloma drug Empliciti afte..
AQ
06/20ABBVIE : 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-An..
AQ
More news
News from SeekingAlpha
06/23Recent Stock Purchase June 2018 
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/22AbbVie's Humira could face pressure from biosimilars, analyst says 
06/22The No. 1 Stock In The World (Redux) - Part 3 
06/211 High-Yield Blue Chip Set To Soar And 1 You Should Ignore 
Financials ($)
Sales 2018 32 922 M
EBIT 2018 14 384 M
Net income 2018 10 789 M
Debt 2018 28 636 M
Yield 2018 3,84%
P/E ratio 2018 13,59
P/E ratio 2019 12,17
EV / Sales 2018 5,38x
EV / Sales 2019 4,97x
Capitalization 148 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 114 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE1.59%148 357
MERCK KGAA-7.21%12 543
KYOWA HAKKO KIRIN CO LTD3.24%12 020
JAZZ PHARMACEUTICALS PLC36.04%10 761
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD77.06%10 382
CONVATEC GROUP10.07%5 660